Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study.

Journal Article (Journal Article)

Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46-year-old white female who presented with progressive hearing loss, severe headaches, nausea, vomiting, and a rapid decline in neurologic status. She was referred to Duke University Medical Center after conventional chemotherapy for malignant melanoma failed. She was enrolled in a Phase I trial of (131)I-labeled monoclonal antibody Mel-14 F(ab')(2) fragment administered intrathecally. Within a year after her treatment, she recovered, having a normal neurologic exam except for residual bilateral hearing loss. The authors discuss dosimetry, preclinical, and clinical studies conducted with Mel-14 F(ab')(2) and introduce a potentially promising therapy option in the treatment of neoplastic meningitis in patients with malignant melanoma. Currently, the patient remains neurologically normal except for a mild bilateral hearing loss more than 4 years after treatment and has no radiographic evidence of neoplastic meningitis.

Full Text

Duke Authors

Cited Authors

  • Cokgor, I; Akabani, G; Friedman, HS; Friedman, AH; Zalutsky, MR; Zehngebot, LM; Provenzale, JM; Guy, CD; Wikstrand, CJ; Bigner, DD

Published Date

  • May 1, 2001

Published In

Volume / Issue

  • 91 / 9

Start / End Page

  • 1809 - 1813

PubMed ID

  • 11335907

International Standard Serial Number (ISSN)

  • 0008-543X


  • eng

Conference Location

  • United States